Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants

AstraZeneca44 enrolled

Overview

This Phase I, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of AZD2693 following subcutaneous (SC) administration of AZD2693 in healthy participants

The study will be performed at a single study center in Japan. The study will comprise of following periods: * Screening Period of maximum 28 days. * An 8-week Treatment Period during which participants will be randomized to receive multiple doses of AZD2693 or placebo at the study center. * A Follow-up Period of 15 weeks post last dose of study intervention consisting of 8 Follow-up Visits. Participants will be enrolled in 4 consecutive cohorts of 11 participants where 8 participants will be randomized to receive AZD2693 and 3 participants will be randomized to receive placebo. A participant is considered to have completed the study if the participant has completed all phases of the study including the last visit.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

TRIPLE

Enrollment

Conditions

Healthy Participants

Interventions

AZD2693DRUG

Participants will receive subcutaneous injection of AZD2693, once per month.

PlaceboDRUG

Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring * Participants who are of Japanese ethnicity (Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese and this also includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan) * Participants who are of Non-Asian ethnicities. A Non-Asian Participant is defined as having both parents and grandparents who are ethnically Non-Asian. * Body mass index within the range 18 to 32 kg/m\^2 * Male and/or female participants of non-child bearing potential Exclusion Criteria: * History of any clinically important disease or disorder * History or presence of gastrointestinal, hepatic, or renal disease or condition known to interfere with absorption, distribution, metabolism or excretion of drugs * Participants with known autoimmune disease or on-treatment with immune-modulatory drugs * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first dose of study intervention * Any clinically significant cardiovascular event within the last 6 months prior to the Screening Visit * Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results and any abnormal vital signs * Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-Lead ECG * Blood dyscrasias with increased risk of bleeding including idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura or symptoms of increased risk of bleeding * History of major bleed or high-risk of bleeding diathesis * Participants with a positive diagnostic nucleic acid test for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), at Screening Visit. Participants who test positive for Coronavirus disease 2019 (COVID-19) at Screening Visit * Participants with a significant COVID-19 illness within 6 months of enrollment * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity * Received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days of last Follow-up to first dose of study intervention of this study or 5 half-lives from last dose to first dose of study intervention, whichever is the longest * Participants who have previously received AZD2693 * Previous enrollment or randomization into the present study

Locations (1)

Research Site

Sumida-ku, Japan

Outcomes

Primary Outcomes

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Safety and tolerability of AZD2693 compared to placebo following multiple dose SC administration in healthy participants will be evaluated.

Time frame: Until Day 162 (Final/Early termination visit)

Secondary Outcomes

Maximum observed plasma drug concentration (Cmax) of AZD2693

Cmax of AZD2693 following single dose SC administration of AZD2693 in healthy participants will be characterized.